[go: up one dir, main page]

WO2019098572A3 - Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus - Google Patents

Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus Download PDF

Info

Publication number
WO2019098572A3
WO2019098572A3 PCT/KR2018/012961 KR2018012961W WO2019098572A3 WO 2019098572 A3 WO2019098572 A3 WO 2019098572A3 KR 2018012961 W KR2018012961 W KR 2018012961W WO 2019098572 A3 WO2019098572 A3 WO 2019098572A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
liver fibrosis
hepatitis virus
fibrosis induced
alleviating liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012961
Other languages
French (fr)
Korean (ko)
Other versions
WO2019098572A2 (en
Inventor
김희선
신현주
김창욱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Industry Academic Cooperation Foundation of Catholic University of Korea
Original Assignee
Daewoong Pharmaceutical Co Ltd
Industry Academic Cooperation Foundation of Catholic University of Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd, Industry Academic Cooperation Foundation of Catholic University of Korea filed Critical Daewoong Pharmaceutical Co Ltd
Publication of WO2019098572A2 publication Critical patent/WO2019098572A2/en
Publication of WO2019098572A3 publication Critical patent/WO2019098572A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a pharmaceutical composition for alleviating liver fibrosis induced by a hepatitis virus, the composition comprising ursodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
PCT/KR2018/012961 2017-11-15 2018-10-30 Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus Ceased WO2019098572A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170152276A KR101887561B1 (en) 2017-11-15 2017-11-15 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis
KR10-2017-0152276 2017-11-15

Publications (2)

Publication Number Publication Date
WO2019098572A2 WO2019098572A2 (en) 2019-05-23
WO2019098572A3 true WO2019098572A3 (en) 2019-07-11

Family

ID=63593798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012961 Ceased WO2019098572A2 (en) 2017-11-15 2018-10-30 Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus

Country Status (2)

Country Link
KR (1) KR101887561B1 (en)
WO (1) WO2019098572A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887561B1 (en) * 2017-11-15 2018-09-06 주식회사 대웅제약 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis
KR102862426B1 (en) * 2022-06-28 2025-09-23 가톨릭대학교 산학협력단 Composition for preventing, improving or treating nonalcoholic steatohepatitis comprising tenofovir alafenamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120008034A (en) * 2009-03-17 2012-01-25 엡탈리스 파마 캐나다 아이엔씨. How to treat nonalcoholic steatohepatitis with increased dose of ursodeoxycholic acid
KR101887561B1 (en) * 2017-11-15 2018-09-06 주식회사 대웅제약 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120008034A (en) * 2009-03-17 2012-01-25 엡탈리스 파마 캐나다 아이엔씨. How to treat nonalcoholic steatohepatitis with increased dose of ursodeoxycholic acid
KR101887561B1 (en) * 2017-11-15 2018-09-06 주식회사 대웅제약 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANZAI, TAIKO ET AL.: "Long-tenn combined therapy with very-low-dose peginierferon and ursodeoxycholic acid decreased the spleen size in a patient with hepatitis C virus-related cirrhosis", INTERNAL MEDICINE, vol. 52, no. 3, 2 November 2012 (2012-11-02) - 2013, pages 363 - 367, XP055619001 *
CORPECHOT, CHRISTOPHE ET AL.: "The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliaiy cirrhosis", HEPATOLOGY, vol. 32, no. 6, 2000, pages 1196 - 1199, XP055618978 *
LONG, LI-HUI ET AL.: "Efficacy of hepatoprotective agents with or without antiviral drugs on liver function and fibrosis in patients with hepatitis B: A meta-analysis", HEPATITIS MONTHLY, vol. 15, no. 7, 22 July 2015 (2015-07-22), pages (e29052)1 - (e29052)12, XP055618982 *
TASCI, ILKER ET AL.: "Rat liver fibrosis regresses better with pegylated interferon alpha 2b and ursodeoxycholic acid treatments than spontaneous recovery", LIVER INTERNATIONAL, vol. 26, no. 2, March 2006 (2006-03-01), pages 261 - 268, XP055618991 *

Also Published As

Publication number Publication date
KR101887561B1 (en) 2018-09-06
WO2019098572A2 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
AU2018351533A8 (en) Crystalline forms and compositions of CFTR modulators
ZA201902053B (en) Pharmaceutical composition
ZA201902051B (en) Pharmaceutical composition
JOP20180071A1 (en) CJ Healthcare Corporation
MX2021010022A (en) Pharmaceutical composition.
HK1246780A1 (en) Aza-pyridone compounds and uses thereof
MX2017012295A (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors.
PH12016502246B1 (en) Carboxamide derivatives
EP3613419A4 (en) Pharmaceutical composition containing indirubin derivative as active ingredient
ZA201902049B (en) Pharmaceutical composition
MX2018001517A (en) Substituted guanidine derivative.
MX2020012989A (en) Therapeutic agent for fibrosis.
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
WO2019194773A3 (en) The combination comprising linagliptin and metformin
MX2016014946A (en) Carboxamide derivatives.
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2019098572A3 (en) Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus
MX2019008338A (en) Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye.
EP4582145A3 (en) Solid state forms of ixazomib citrate
MX2016013439A (en) Solid forms of a pharmaceutically active compound.
EP3964218A4 (en) Pharmaceutical composition for preventing or treating myositis, comprising isolated mitochondria as active ingredient
MX394413B (en) Pharmaceutical composition containing clomipramine and preparation method therefor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18877363

Country of ref document: EP

Kind code of ref document: A2